Home > Press > Arrowhead Receives and Responds to Notification of Minimum Stockholders’ Equity Non-Compliance from the NASDAQ Stock Market
Abstract:
Arrowhead Research Corporation (NASDAQ:ARWR) announced that it received a notification letter from The NASDAQ Stock Market ("NASDAQ") indicating that its stockholders' equity, based on its Form 10-Q for the period ended March 31, 2009, does not comply with NASDAQ Marketplace Rule 4310(c)(3), which requires companies listed on The NASDAQ Capital Market to maintain a minimum of $2.5 million in stockholders' equity. Today Arrowhead submitted a plan to regain and sustain compliance with the minimum stockholder equity requirement. If accepted by NASDAQ, the Company may be provided with up to 105 calendar days to demonstrate compliance. The NASDAQ notification does not affect the listing of Arrowhead's common stock at this time.
Commenting on the receipt of the NASDAQ's notification letter, Dr. Christopher Anzalone, CEO of Arrowhead, stated, "We have prepared and submitted to NASDAQ a plan to regain and sustain compliance with the exchange's minimum stockholders' equity requirement. We are taking action to strengthen our balance sheet to put Arrowhead on a stronger financial footing and expect this will be reflected in our results for the quarter ending June 30, 2009."
####
About Arrowhead Research Corporation
Arrowhead Research Corporation (www.arrowheadresearch.com) (NASDAQ:ARWR) is a nanotechnology company commercializing new technologies in the areas of life sciences, electronics, and energy. Arrowhead is seeking to build value for shareholders through the progress of majority owned subsidiaries. Currently, Arrowhead has four subsidiaries commercializing nanotech products and applications and investments in two minority-owned subsidiaries.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995:
This news release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon our current expectations and speak only as of the date hereof. Our actual results may differ materially and adversely from those expressed in any forward-looking statements as a result of various factors and uncertainties. For example, there can be no assurance that we will be able to maintain our listing on any NASDAQ market, that our financial initiatives will succeed in strengthening our balance sheet or that we will be able to continue to operate as a going concern. Arrowhead Research Corporation's Annual Report on Form 10-K and 10-K/A, recent and forthcoming Quarterly Reports on Form 10-Q and 10-Q/A, recent Current Reports on Forms 8-K and 8-K/A, our Registration Statements on Form S-3, and other SEC filings discuss these and other important risk factors that may affect our business, results of operations and financial condition. We disclaim any intent to revise or update publicly any forward-looking statements.
For more information, please click here
Contacts:
Investor Relations Contact:
Sanjay M. Hurry
The Piacente Group, Inc.
212-481-2050
Copyright © Business Wire 2009
If you have a comment, please Contact us.Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
Related News Press |
News and information
Beyond wires: Bubble technology powers next-generation electronics:New laser-based bubble printing technique creates ultra-flexible liquid metal circuits November 8th, 2024
Nanoparticle bursts over the Amazon rainforest: Rainfall induces bursts of natural nanoparticles that can form clouds and further precipitation over the Amazon rainforest November 8th, 2024
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Investments/IPO's/Splits
Daikin Industries becomes OCSiAl shareholder July 27th, 2021
INBRAIN Neuroelectronics raises over €14M to develop smart graphene-based neural implants for personalised therapies in brain disorders March 26th, 2021
180 Degree Capital Corp. Issues Second Open Letter to the Board and Shareholders of Enzo Biochem, Inc. March 26th, 2021
Announcements
Nanotechnology: Flexible biosensors with modular design November 8th, 2024
Exosomes: A potential biomarker and therapeutic target in diabetic cardiomyopathy November 8th, 2024
Turning up the signal November 8th, 2024
Nanofibrous metal oxide semiconductor for sensory face November 8th, 2024
The latest news from around the world, FREE | ||
Premium Products | ||
Only the news you want to read!
Learn More |
||
Full-service, expert consulting
Learn More |
||